Virtu Financial’s Immuneering IMRX Stock Holding History

Virtu Financial’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,994	Closed	-$98K	–	1921
2025 Q3	$98K	Buy	+13,994	New	+$72.6K	0.01%	1046
2024 Q1	–	Sell	-11,409	Closed	-$84K	–	1717
2023 Q4	$84K	Buy	+11,409	New	+$76K	0.01%	1065

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial's IMRX Position: Q4 2025 in Review

Virtu Financial sold out of Immuneering (IMRX) in Q4 2025, closing a stake of 13,994 shares — an estimated $98K sold.

Virtu Financial first reported a position in IMRX in Q4 2023 and held it in 2 quarters. The position peaked at $98K in Q3 2025. 86 funds tracked by Wall St. Rank hold IMRX as of Q4 2025.

Virtu Financial reported no remaining Immuneering position as of Q4 2025 after selling out during the quarter.
Virtu Financial sold 13,994 Immuneering shares in Q4 2025, an estimated $98K.
Virtu Financial first reported a position in Immuneering in Q4 2023 and held it in 2 quarters.
Virtu Financial's Immuneering position peaked at $98K in Q3 2025.
86 funds tracked by Wall St. Rank held Immuneering as of Q4 2025.

Based on Virtu Financial's 13F filing for Q4 2025, filed 23 Feb 2026.